News from merck A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 01, 2020, 10:00 ET Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors

Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Merck, known as MSD outside the United States and Canada, has licensed its first TriNKET™ immunotherapy candidate from Dragonfly....


Oct 15, 2020, 07:00 ET Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial KEYTRUDA® is an anti-PD-1 therapy that works by helping increase the ability of the body's immune system to help ...


Sep 24, 2020, 07:00 ET NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada

NEXPLANON® is the first single-rod arm implant to be approved by Health Canada for the prevention of pregnancy.1 The implant provides Canadians with a new birth control option that can be removed at...


Sep 15, 2020, 07:00 ET BRENZYS® (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis

BRENZYS® is a biosimilar biologic drug authorized based on its similarity to ENBREL®, which is already approved for use in Canada.1 Approximately one million people in Canada live with psoriasis,2...


May 12, 2020, 08:00 ET Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Skyhawk Therapeutics, Inc. ("Skyhawk") today announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and...


Mar 19, 2020, 09:00 ET Dragonfly Therapeutics Announces Multi-Target Expansion of its Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Therapeutic Candidates in the fields of

Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced an expansion of its strategic collaboration with Merck, known as MSD outside the United States and Canada to discover, develop and...


Mar 04, 2020, 08:01 ET Redefining Cancer Treatment Shines Light on Cancer Immunotherapies

Campaign features the stories of Canadians impacted by different types of cancer KIRKLAND, QC, March 4, 2020 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada launches a...


Jan 23, 2020, 07:31 ET Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

Approval Based on Results of KEYNOTE-426, Where KEYTRUDA® in Combination with Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib Renal cell carcinoma (RCC) is the most common...


Nov 18, 2019, 07:00 ET Ontario and Quebec provide reimbursement for HIV therapies PIFELTRO® (doravirine) and DELSTRIGO® (doravirine/lamivudine/tenofovir disoproxil fumarate)

Although treatment progress has been made, human immunodeficiency virus (HIV) is still one of the world's most serious public health challenges.i In 2018, approximately 37.9 million people were...


Nov 08, 2019, 08:00 ET Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial

Merck and Pfizer Inc. (NYSE: PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction chemotherapy in...


Jul 08, 2019, 07:30 ET Skyhawk Therapeutics Announces Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered a strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and...


Mar 18, 2019, 08:00 ET New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer

KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared to Chemotherapy Alone Every day, approximately 78 Canadians are diagnosed ...


Jan 24, 2019, 08:00 ET Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Not intended for UK- or US-based media Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas...


Nov 19, 2018, 17:09 ET Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in life sciences

MONTREAL, Nov. 19, 2018 /CNW Telbec/ - CQDM is delighted to announce that Merck Canada, a founding member of the consortium, is renewing its commitment with a $3.5M contribution to support the...


Oct 11, 2018, 13:30 ET Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

Not intended for U.S media Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS #MSInsideOut documentary film,...


Oct 01, 2018, 08:58 ET Dragonfly Therapeutics Announces New Multi-Target Collaboration with Merck to Use Dragonfly's Proprietary TriNKET™ Platform to Develop Novel Drug Candidates for Patients with Solid Tumors

Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and...


Jun 04, 2018, 09:32 ET Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814...


Jun 03, 2018, 08:30 ET Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

/NOT INTENDED FOR UK- OR US-BASED MEDIA/ DARMSTADT, Germany, June 3, 2018 /CNW/ - ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566;...


Mar 27, 2018, 08:40 ET Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan

/NOT INTENDED FOR UK- OR US-BASED MEDIA/ Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE designation for tepotinib, Merck's investigational highly selective c-Met receptor tyrosine...


Jan 18, 2018, 04:00 ET The Consumer Health of Merck Walks the Talk with its WE100 Movement

DARMSTADT, Germany, Jan. 18, 2018 /CNW/ - Consumer Health accelerates its WE100® movement by launching new partnership programme with pharmacists in the UK on enabling 100 years of healthy living...


Dec 21, 2017, 14:04 ET FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] Javelin Renal...


Nov 07, 2017, 04:00 ET Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years

New whitepaper from Consumer Health business shines light on preparing the young generation for living 100 healthy years Whitepaper focuses on the importance to adopt good health habits early on to...


Aug 08, 2017, 05:57 ET NICE Recommends Erbitux® in Combination with Platinum-Based Chemotherapy for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer in the Oral Cavity

DARMSTADT, Germany, Aug. 8, 2017 /CNW/ - Not intended for U.K./U.S. based media Decision secures access to Erbitux® for new patients in England with oral cavity tumors All patients currently...


Jul 10, 2017, 07:00 ET PDS Biotechnology Corp. Announces Clinical Collaboration with Merck to Evaluate Combination of Versamune® PDS0101 and KEYTRUDA® (pembrolizumab) for Metastatic Head and Neck Cancer

PDS Biotechnology Corporation ("PDS"), a private clinical stage immuno-oncology company developing novel immunotherapies, has entered a clinical trial collaboration agreement with a subsidiary of...


May 19, 2017, 04:00 ET 100 Healthy Years - Are Kids Prepared?

Merck Consumer Health's Annual Debate: global expert discussion on how to prepare children to live 100 healthy years Global study of the Economist Intelligence Unit: today's children will be less...